Keybanc Maintains Overweight on AbCellera Biologics, Lowers Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
Keybanc analyst Scott Schoenhaus maintains an Overweight rating on AbCellera Biologics (NASDAQ:ABCL) but lowers the price target from $8 to $7.
May 08, 2024 | 6:18 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Keybanc maintains an Overweight rating on AbCellera Biologics but lowers the price target from $8 to $7.
While the reduction in price target could suggest a tempered outlook on the stock's short-term price performance, the maintenance of an Overweight rating indicates a continued positive long-term view on the company by Keybanc. This mixed signal could lead to neutral short-term price movement as investors digest both the positive rating and the lower price target.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100